New 'De-Chemo' combo aims to shrink tumors for better surgery in ovarian cancer
NCT ID NCT07033819
Summary
This study is testing a two-drug combination (fuzuloparib and apatinib) as a treatment given before surgery for advanced ovarian cancer. The goal is to see if this non-chemotherapy approach can shrink tumors enough to make complete surgical removal more likely, potentially improving patient outcomes. It is for patients whose cancer has a specific genetic feature called HRD-positive.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.